| Sanjay Bardwaj, DPT | |
|
104 Old Las Vegas Hwy, Santa Fe, NM 87505 | |
| (505) 992-4995 | |
| (505) 992-4985 |
| Full Name | Sanjay Bardwaj |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 23 Years |
| Location | 104 Old Las Vegas Hwy, Santa Fe, New Mexico |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093184186 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 4637 (New Mexico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Van Pelt And Associates Physical Therapy Services Pa | 1951463454 | 15 |
News Archive
With the first detailed analysis of a cellular component from a close relative of the pathogen that causes tuberculosis, Rockefeller scientists are suggesting strategies for new drugs to curb this growing health problem.
A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
A funding analysis released on Wednesday by the Kaiser Family Foundation (KFF) and UNAIDS found that "funding to fight HIV/AIDS in low- and middle-income countries has remained flat at $7.6 billion," Politico Pro reports.
› Verified 4 days ago
| Entity Name | Van Pelt & Associates Physical Therapy Services Pa |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1619018504 PECOS PAC ID: 1951463454 Enrollment ID: O20081217000403 |
News Archive
With the first detailed analysis of a cellular component from a close relative of the pathogen that causes tuberculosis, Rockefeller scientists are suggesting strategies for new drugs to curb this growing health problem.
A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
A funding analysis released on Wednesday by the Kaiser Family Foundation (KFF) and UNAIDS found that "funding to fight HIV/AIDS in low- and middle-income countries has remained flat at $7.6 billion," Politico Pro reports.
› Verified 4 days ago
| Entity Name | Tenet Florida Physician Services Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912266420 PECOS PAC ID: 1456507698 Enrollment ID: O20120803000519 |
News Archive
With the first detailed analysis of a cellular component from a close relative of the pathogen that causes tuberculosis, Rockefeller scientists are suggesting strategies for new drugs to curb this growing health problem.
A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
A funding analysis released on Wednesday by the Kaiser Family Foundation (KFF) and UNAIDS found that "funding to fight HIV/AIDS in low- and middle-income countries has remained flat at $7.6 billion," Politico Pro reports.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sanjay Bardwaj, DPT 104 Old Las Vegas Hwy, Santa Fe, NM 87505 Ph: (505) 992-4995 | Sanjay Bardwaj, DPT 104 Old Las Vegas Hwy, Santa Fe, NM 87505 Ph: (505) 992-4995 |
News Archive
With the first detailed analysis of a cellular component from a close relative of the pathogen that causes tuberculosis, Rockefeller scientists are suggesting strategies for new drugs to curb this growing health problem.
A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
A funding analysis released on Wednesday by the Kaiser Family Foundation (KFF) and UNAIDS found that "funding to fight HIV/AIDS in low- and middle-income countries has remained flat at $7.6 billion," Politico Pro reports.
› Verified 4 days ago
Dr. Beth Palmisano, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1631 Hospital Dr, Suite 110, Santa Fe, NM 87505 Phone: 505-982-7246 Fax: 505-983-4812 | |
Lynda Holliday, RN-BC Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 542 Juniper Dr, Santa Fe, NM 87501 Phone: 505-982-8314 | |
Nicole B Golding, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 455 Saint Michaels Dr, Santa Fe, NM 87505 Phone: 505-913-5470 Fax: 505-913-6489 | |
Dr. Yan Yang, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2801 Rodeo Rd, Suite F, Santa Fe, NM 87507 Phone: 505-438-7178 Fax: 505-438-1056 | |
Dr. Theresa Michelle Genovese Elliott, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 4801 Beckner Rd Level 1 Pod 2, Ste 1650, Santa Fe, NM 87507 Phone: 505-772-2000 Fax: 505-983-5202 | |
Sean B Horner, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1850 Calle Medico Ste H, Santa Fe, NM 87505 Phone: 303-519-4816 |